In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

US pharma giant Pfizer has provided a reminder of the merits of mRNA-based vaccines as health leaders in the USA continue to question their safety.

Pfizer rises after a study found that the company's new mRNA flu vaccine outperforms traditional shots against predominant strains.

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...

More than 20 COVID vaccines are in use globally, each one based on the ancestral coronavirus SARS-CoV-2 that surfaced in Wuhan, China, over two years ago. Among them, mRNA vaccines are believed to ...